AU409 for Advanced Liver Cancers or Solid Tumors
Phase 1
36
about 4 years
18+
2 sites in CA
What this study is about
This trial is testing the safety, side effects, and best dose of a new intervention called AU409 in people with advanced liver cancers or solid tumors that have spread to the liver. The goal is to see if AU409 can stop cancer from growing and spreading.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take RNA Transcription Modulator AU-409
- 2.Undergo Biospecimen Collection
- 3.Undergo Computed Tomography
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events, Maximum Tolerated Dose
Secondary: Pharmacokinetics evaluation - Peak plasma concentration (Cmax), Pharmacokinetics evaluation - Peak time (Tmax)
diagnostic, imaging
Oncology